Molecular Diagnostics
Liquid Biopsy Identifies Mutations Predicting Ovarian Cancer Treatment Response
Effective treatment of metastatic solid cancers is hampered by intrapatient heterogeneity, tumor evolution, and the paucity of representative tissue samples to guide treatment decisions. Analysis of circulating tumor DNA (ctDNA) is an approach with the potential of overcoming all three obstacles. More...29 May 2019
Blood Test Measures Effectiveness of Aggressive Cancer Treatments
Blood tests that track the amount of tumor DNA can, after only one month of drug therapy, detect how well treatment is working in patients with skin cancer. In the USA, more than 7,200 individuals are expected to die from metastatic melanoma in 2019, with BRAF mutations playing a role in nearly half of such diagnoses. More...27 May 2019
Rapid Assay Detects Pyrazinamide-Resistant Tuberculosis
Tuberculosis (TB), caused by Mycobacterium tuberculosis complex (MTBC) strains, remains one of the most frequent infectious diseases worldwide. Due to its high frequency and the increased risk of co-resistance to other drugs, rapid detection of pyrazinamide (PZA) resistance is essential to control the MDR-TB epidemic. More...27 May 2019
Assay Stratifies Esophageal Cancer Patients for Treatment
The incidence of esophageal adenocarcinoma (OAC) in the Western world has risen six-fold in the last 40 years with the highest incidence occurring in the UK and there were about 9,200 cases of the disease reported in the UK in 2015. It accounts for 3% of cancer cases in the UK each year. More...22 May 2019
Clinical Trial Highlights Poor Prognosis for Bladder Cancer Patients
Analysis of the IMvigor 210 clinical trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma (the most common type of bladder cancer) who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker that may aid in development of personalized treatment of the disease. More...20 May 2019
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
In Other News
Prostate Cancer Severity Indicated by Location and Concentration of Syntaphilin
Clinical Validation Bolsters Liquid Biopsy Evidence Base
Serum HBV RNA Quantification Monitors Chronic Hepatitis B Infection
Breast Cancer Test Determines Most Effective Treatment
Urine Test Could Prevent Cervical Cancer
Biomarker Predicts Appropriate Immunotherapy for Cancer Patients
Oral HPV-DNA Persists after Oropharyngeal Cancer Treatment
Liquid Biopsy Utility Reinforced in Early Cancer Trials Results
Machine-Learning System Used to Diagnose Genetic Diseases
New Genetic Test Detects Mutations in High-Risk Groups
Sequencing Shows Promise for Diagnosing Prosthetic Joint Infections
Neurofilament Light Considered as NIV Biomarker for Alzheimer's Disease
Diagnostic Methods Compared for Human Granulocytic Anaplasmosis
Personalized Detection of ctDNA Antedates Breast Cancer
Novel Genes and Pathways Discovered in Celiac Disease
Protein Atlas Accelerates Personalized Medicine in Leukemia Patients
Biomarkers of Oral Cancer Discovered
Human Microbiome Features Stratify Children with IBS
Unexplained Liver Disease Diagnosed by Whole-Exome Sequencing
Multi-Gene Panel Testing Catches Cancer Risk Variants
High-Res Genotyping Improves Survival for Stem Cell Transplantation
Sequencing Finds Germline Risk Variants in Pediatric Cancer Cases
Biochip Assay Rapidly Detects Mycobacterial Isolates
Genetic Testing channel of LabMedica brings the latest in molecular genetics, cytogenetics, and epigenetics, and methods from PCR to FISH, and more.
